Opinion|Videos|September 11, 2024
Future Research Needs for Neoadjuvant/Adjuvant PD-1 Blockade in Nasopharyngeal Carcinoma
The panel provides clinical insights on nasopharyngeal carcinoma treatment practices and outlines unmet needs in the current therapeutic landscape.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- What further research is needed to better understand the long-term benefits and risks of neoadjuvant/adjuvant PD-1 blockade this patient population?
Advertisement
Related to this article
Neoadjuvant and adjuvant pembrolizumab improved EFS across surgical outcome subgroups in resectable head and neck squamous cell carcinoma.
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts NDA for Mezigdomide Plus Kd in R/R Myeloma
2
Dostarlimab Achieves Sustained Clinical Complete Responses in dMMR/MSI-H Rectal Cancer
3
Dive Into Key Data and Presentations From EHA 2026
4
Access, Sequencing Considerations Remain Key Focal Points for CAR T-Cell Therapy in R/R Myeloma
5